TACSTD2 and triple-negative breast carcinoma: Based on the pan-cancer expression of Trop2, it is currently utilised as a target for antibody–drug conjugates (ADCs) in third-line treatment of triple-negative breast cancer, with several ongoing clinical trials exploring the safety profiles and efficacy of novel Trop2-targeted therapies (Bardia et al, 2021a).